Vaxcyte, Inc. (NASDAQ:PCVX) CFO Andrew Guggenhime Sells 8,000 Shares

Vaxcyte, Inc. (NASDAQ:PCVX) CFO Andrew Guggenhime sold 8,000 shares of the company’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $83.85, for a total transaction of $670,800.00. Following the transaction, the chief financial officer now directly owns 109,491 shares in the company, valued at $9,180,820.35. The trade was a 6.81 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link.

Andrew Guggenhime also recently made the following trade(s):

• On Tuesday, January 21st, Andrew Guggenhime sold 8,000 shares of Vaxcyte stock. The shares were sold at an average price of $86.51, for a total transaction of $692,080.00.
• On Wednesday, December 18th, Andrew Guggenhime sold 8,000 shares of Vaxcyte stock. The shares were sold at an average price of $88.78, for a total transaction of $710,240.00.

Vaxcyte Stock Up 1.1 %

Vaxcyte stock opened at $83.36 on Thursday. Vaxcyte, Inc. has a 52-week low of $58.10 and a 52-week high of $121.06. The firm has a fifty day moving average of $85.88 and a 200-day moving average of $94.65. The firm has a market capitalization of $10.39 billion, a P/E ratio of -18.12 and a beta of 0.98.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Vaxcyte in a research note on Wednesday, November 6th. Needham & Company LLC reaffirmed a “buy” rating and set a $14.00 price target on shares of Vaxcyte in a research note on Tuesday, February 11th. Finally, The Goldman Sachs Group assumed coverage on shares of Vaxcyte in a research note on Friday, December 20th. They set a “buy” rating and a $135.00 price target on the stock. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $127.71.

Institutional Investors Weigh In On Vaxcyte

Large investors have recently made changes to their positions in the business. Whipplewood Advisors LLC acquired a new stake in shares of Vaxcyte in the fourth quarter worth $28,000. Smartleaf Asset Management LLC increased its position in shares of Vaxcyte by 188.4% in the fourth quarter. Smartleaf Asset Management LLC now owns 398 shares of the company’s stock worth $33,000 after acquiring an additional 260 shares in the last quarter. National Bank of Canada FI acquired a new stake in shares of Vaxcyte in the fourth quarter worth $41,000. Blue Trust Inc. increased its position in shares of Vaxcyte by 33.5% in the third quarter. Blue Trust Inc. now owns 371 shares of the company’s stock worth $42,000 after acquiring an additional 93 shares in the last quarter. Finally, Assetmark Inc. increased its position in shares of Vaxcyte by 77,500.0% in the fourth quarter. Assetmark Inc. now owns 776 shares of the company’s stock worth $64,000 after acquiring an additional 775 shares in the last quarter. Institutional investors and hedge funds own 96.78% of the company’s stock.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.